Adverse Drug Event: Clinical Trials

5 trials for Adverse Drug Event, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown, 2 completed. 5 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Unknown 3, Completed 2
Phase 12Completed 1, Unknown 1

Follow Adverse Drug Event: new trials by email Literature Review of Adverse Drug Event trials Research Report on Adverse Drug Event

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of GC101 TIL in Advanced Melanoma (BZ)
GC101 TIL - Tumor Infiltrating Lymphocytes, Safety
Phase 1 / Phase 2CompletedShanghai Juncell Therapeutics182023-11-082025-12-23
Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas
Drug therapy - Chemotherapy, Anti-pd-1 Antibody
Phase 2UnknownLei Li202020-11-152020-11-19
TIL and Anti-PD1 in Metastatic Melanoma
Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha - Toxicity, Drug, Adverse Drug Event
Phase 1 / Phase 2UnknownLeiden University342018-07-312023-12-12
Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients
Prapchompoothaweep remedy, Loratadine 10 Mg - Allergic Rhinitis, Adverse Drug Event
Phase 2CompletedThammasat University722017-11-232018-08-22
Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
pazopanib - Self Efficacy, Adverse Drug Event
Phase 2UnknownSouthern China Urology Cancer Consortium862014-07-012014-12-24

Narrower conditions

Drug-Related Side Effects and Adverse Reactions (5)  ·  Melanoma (2)  ·  Carcinoma, Renal Cell (1)  ·  Rhinitis, Allergic (1)  ·  Uterine Cervical Neoplasms (1)

Broader conditions

Chemically-Induced Disorders (5)  ·  Neoplasms (4)  ·  Neoplasms by Site (4)  ·  Neoplasms by Histologic Type (3)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Neoplasms, Germ Cell and Embryonal (2)  ·  Neoplasms, Nerve Tissue (2)  ·  Neuroectodermal Tumors (2)  ·  Neuroendocrine Tumors (2)  ·  Nevi and Melanomas (2)  ·  Skin Diseases (2)  ·  Skin Neoplasms (2)  ·  Skin and Connective Tissue Diseases (2)  ·  Urogenital Diseases (2)

Interventions

Drug Therapy (1)  ·  Loratadine (1)  ·  Nivolumab (1)  ·  pazopanib (1)

Sponsors

Lei Li (1)  ·  Leiden University (1)  ·  Shanghai Juncell Therapeutics (1)  ·  Southern China Urology Cancer Consortium (1)  ·  Thammasat University (1)

Countries

China (3)  ·  Netherlands (1)  ·  Thailand (1)

Top investigators

Ellen Kapiteijn, Dr. (1)  ·  Jun Guo (1)  ·  Lei Li, M.D. (1)  ·  Mian Xie (1)

Results publications

PMID 33234662